	US 12,280,118 B2
	IL-2 variant
Masahiro Ikeda, Tokyo (JP); Shinpei Yamaguchi, Tokyo (JP); Masumi Murakami, Tokyo (JP); and Hideyuki Onodera, Tokyo (JP)
Assigned to KYOWA KIRIN CO., LTD., Tokyo (JP)
Appl. No. 16/958,045
Filed by Kyowa Kirin Co., Ltd., Tokyo (JP)
PCT Filed Dec. 27, 2018, PCT No. PCT/JP2018/048361 § 371(c)(1), (2) Date Jun. 25, 2020, PCT Pub. No. WO2019/131964, PCT Pub. Date Jul. 4, 2019.
Claims priority of application No. 2017-252224 (JP), filed on Dec. 27, 2017.
Prior Publication US 2021/0060169 A1, Mar. 4, 2021
Int. Cl. A61K 47/60 (2017.01); A61K 38/20 (2006.01); A61K 47/54 (2017.01)

CPC A61K 47/60 (2017.08) [A61K 38/2013 (2013.01); A61K 47/545 (2017.08)]

13 Claims

1. An Interleukin-2 (IL-2) variant having improved selectivity for an IL-2 receptor (IL-2R)_αβγ, wherein the IL-2 variant is a polyethylene glycol (PEG)-bound IL-2 variant comprising an amino acid sequence in which amino acid residues at one or more of positions 4, 5, 6, 7, 8, 60, 78, 79, 99, 100, 101, and 129 in the amino acid sequence represented by SEQ ID NO: 1 are substituted with a PEGylated non-natural amino acid residue derived from an N⁶-[{(o-azidobenzyl) oxy}carbonyl]-L-lysine (o-Az-Z-Lys) residue or derived from an N⁶-[{(m-azidobenzyl)oxy}carbonyl]-L-lysine (m-Az-Z-Lys) residue.